{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:02:25Z","timestamp":1781186545544,"version":"3.54.1"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T00:00:00Z","timestamp":1447200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Cancer patients in developing and low\u2010income countries have limited access to target therapies. For example, tyrosine kinase inhibitor (<jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>) therapy for chronic myeloid leukaemia patients (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>) is often delayed. In Bosnia, 16% of patients received immediate <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> treatment (&lt;3\u00a0months of diagnosis), while 66% of patients received therapy after a median 14\u2010month wait period. To assess the effect of delayed treatment on outcome, three patient groups were studied according to the time they received <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> treatment (0\u20135\u00a0months, 6\u201312\u00a0months and &gt;13\u00a0months delay). The primary endpoints were complete cytogenetic (<jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content>yR) and major molecular response (<jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content>) at 12\u00a0months. At 12\u00a0months of therapy, <jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content>yR and <jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content> rates on imatinib decreased significantly: <jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content>yR was achieved in 67% of patients in the immediate imatinib treatment group, 18% of patients in 6\u201312\u00a0months group and 15% of patients in &gt;13\u00a0months wait group. <jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content> rates at 12\u00a0months occurred in 10% of patients with immediate treatment, 6% of those in 6\u201312\u00a0months group and 0% of patients in &gt;13\u00a0months wait group. However, <jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content>yR and <jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content> rates in patients on nilotinib were not associated with duration of treatment delay. Our data suggests that the deleterious effect of a prolonged <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> therapy delay may be ameliorated by the more active <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> nilotinib.<\/jats:p>","DOI":"10.1111\/bjh.13843","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T09:30:39Z","timestamp":1447234239000},"page":"420-427","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The reality of cancer treatment in a developing country: the effects of delayed <scp>TKI<\/scp> treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients"],"prefix":"10.1111","volume":"172","author":[{"given":"Amina","family":"Kurtovic\u2010Kozaric","sequence":"first","affiliation":[{"name":"Department of Pathology University Clinical Centre Sarajevo Sarajevo Bosnia and Herzegovina"},{"name":"Department of Biology Faculty of Natural Sciences University of Sarajevo Sarajevo Bosnia and Herzegovina"},{"name":"Department of Genetics and Bioengineering International Burch University Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Hasic","sequence":"additional","affiliation":[{"name":"Department of Biology Faculty of Natural Sciences University of Sarajevo Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"Bijedic","sequence":"additional","affiliation":[{"name":"Haematology Clinic University Clinical Centre Sarajevo Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilada","family":"Nefic","sequence":"additional","affiliation":[{"name":"Department of Biology Faculty of Natural Sciences University of Sarajevo Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izet","family":"Eminovic","sequence":"additional","affiliation":[{"name":"Department of Biology Faculty of Natural Sciences University of Sarajevo Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabira","family":"Kurtovic","sequence":"additional","affiliation":[{"name":"Haematology Clinic University Clinical Centre Sarajevo Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferida","family":"Colakovic","sequence":"additional","affiliation":[{"name":"Haematology Clinic Cantonal Hospital Zenica Zenica Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza","family":"Kozaric","sequence":"additional","affiliation":[{"name":"Centre for Mother and Child University Clinical Centre Sarajevo Sarajevo Bosnia and Herzegovina"},{"name":"Department of Genetics and Bioengineering International Burch University Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semir","family":"Vranic","sequence":"additional","affiliation":[{"name":"Department of Pathology University Clinical Centre Sarajevo Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada S.","family":"Bovan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Clinical Hospital Mostar Mostar Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.578310"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-319038"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"},{"key":"e_1_2_8_12_1","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell P.C.","year":"1960","journal-title":"Science"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-229864"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13843","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:07:52Z","timestamp":1696324072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/bjh.13843"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13843","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,11]]},"assertion":[{"value":"2015-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}